Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.

PD-1 Blockade Expands Intratumoral Memory T Cells

Open access

Published version of a preprint

Abstract

Tumor responses to programmed cell death protein 1 (PD-1) blockade therapy are mediated by T cells, which we characterized in 102 tumor biopsies obtained from 53 patients treated with pembrolizumab, an antibody to PD-1. Biopsies were dissociated, and single-cell infiltrates were analyzed by multicolor flow cytometry using two computational approaches to resolve the leukocyte phenotypes at the single-cell level. There was a statistically significant increase in the frequency of T cells in patients who responded to therapy. The frequency of intratumoral B cells and monocytic myeloid-derived suppressor cells significantly increased in patients' biopsies taken on treatment. The percentage of cells with a regulatory T-cell phenotype, monocytes, and natural killer cells did not change while on PD-1 blockade therapy. CD8+ memory T cells were the most prominent phenotype that expanded intratumorally on therapy. However, the frequency of CD4+ effector memory T cells significantly decreased on treatment, whereas CD4+ effector T cells significantly increased in nonresponding tumors on therapy. In peripheral blood, an unusual population of blood cells expressing CD56 was detected in two patients with regressing melanoma. In conclusion, PD-1 blockade increases the frequency of T cells, B cells, and myeloid-derived suppressor cells in tumors, with the CD8+ effector memory T-cell subset being the major T-cell phenotype expanded in patients with a response to therapy. Cancer Immunol Res; 4(3); 194–203. ©2016 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/2326-6066.cir-15-0210

Cites

51 of 51 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 51 references

Cited by

See all 405

Metadata

Authors
Ribas, A., Shin, D. S., Zaretsky, J., Frederiksen, J., Cornish, A., Avramis, E., Seja, E., Kivork, C., Siebert, J., Kaplan-Lefko, P., Wang, X., Chmielowski, B., Glaspy, J. A., Tumeh, P. C., Chodon, T., Pe'er, D., & Comin-Anduix, B.
Affiliations
  • University of California, Los Angeles (US)
  • Technical University of Denmark (DK)
  • Columbia University (US)
  • 7CytoAnalysis, Denver, Colorado.
  • 1Division of Hematology-Oncology, Department of Medicine, University of California Los Angeles, Los Angeles, California.
  • Roswell Park Comprehensive Cancer Center (US)
  • 6Departments of Biological Sciences and Systems Biology, Columbia University, New York, New York.
  • 2Division of Surgical-Oncology, Department of Surgery, University of California Los Angeles, Los Angeles, California.
Corresponding author
Ribas, Antoni
Venue
Cancer Immunology Research
Published
2016-02-29
Volume
4
Issue
3
Pages
194-203
ISSN
  • 2326-6066 (ISSN-L)
  • 2326-6074
OpenAlex
W2281666530
Cited by
405
References
51
Citations by year
2026: 23 · 2025: 21 · 2024: 36 · 2023: 40 · 2022: 38 · 2021: 44 · 2020: 58 · 2019: 61 · 2018: 35 · 2017: 36 · 2016: 13
FWCI
26.03
Type
journal article
Language
en
Open access
Locations
  • Cancer Immunology Research (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
  • eScholarship (California Digital Library) (submittedVersion)
  • Technical University of Denmark, DTU Orbit (Technical University of Denmark, DTU) (submittedVersion, other-oa)
Funders
  • NIH, Cancer Research Institute and Cancer Immunology Dream Team Translational Research (R35 CA197633, P01 CA168585, SU2C-CRI, SU2C-AACR-DT1012)
  • Cancer Phillip A. Sharp Innovation (SU2C-AACR-PS04)
  • Tower Cancer Research Foundation (5T32CA009297-30, 5T32AR058921-05, 5T32CA009120-39)
  • NIH and JCCC, JCCC, the UCLA AIDS Institute, and the David Geffen School of Medicine at UCLA (CA16042, AI 28697)
Topics
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Keywords
anti-PD-1 therapy, pembrolizumab, intratumoral T cells, memory CD8+ T cells, CD4+ effector memory T cells, myeloid-derived suppressor cells, tumor-infiltrating B cells, melanoma regression, antitumor immunity, cancer immunotherapy
MeSH terms
Aged, Antineoplastic Agents, Female, Humans, Male, Melanoma, Middle Aged, Skin Neoplasms, T-Lymphocyte Subsets, Treatment Outcome, Programmed Cell Death 1 Receptor, Antibodies, Monoclonal, Humanized

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: PD-1 Blockade Expands Intratumoral Memory T Cells. https://app.cochat.ai/papers/10.1158/2326-6066.cir-15-0210
The paper
Ribas, A., Shin, D. S., Zaretsky, J., Frederiksen, J., Cornish, A., Avramis, E., Seja, E., Kivork, C., Siebert, J., Kaplan-Lefko, P., Wang, X., Chmielowski, B., Glaspy, J. A., Tumeh, P. C., Chodon, T., Pe'er, D., & Comin-Anduix, B. (2016). PD-1 Blockade Expands Intratumoral Memory T Cells. Cancer Immunology Research. https://doi.org/10.1158/2326-6066.cir-15-0210

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.